Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review | Zendy

Howard J. Lim | Zendy; Ravi Ramjeesingh | Zendy; David Liu | Zendy; Vincent C. Tam | Zendy; Jennifer J. Knox | Zendy; Paul Card | Zendy; Brandon M. Meyers | Zendy

Open Access

Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review

Author(s) -

Howard J. Lim,

Ravi Ramjeesingh,

David Liu,

Vincent C. Tam,

Jennifer J. Knox,

Paul Card,

Brandon M. Meyers

Publication year - 2020

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djaa119

Subject(s) - sorafenib , regorafenib , medicine , lenvatinib , bevacizumab , oncology , ramucirumab , targeted therapy , hepatocellular carcinoma , atezolizumab , cabozantinib , clinical trial , nivolumab , cancer , overall survival , chemotherapy , immunotherapy , colorectal cancer

Systemic therapy for hepatocellular carcinoma (HCC) consisting of the tyrosine kinase inhibitor sorafenib has remained unchanged for over a decade, although results from phase III targeted therapy trials have recently emerged. This review considers available phase III evidence on the use and sequencing of targeted therapy for intermediate and advanced non-locoregional therapy (LRT) eligible HCC and discusses implications for clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research